SAFETY AND EFFICACY OF UPADACITINIB (ABT-494), AN ORAL JAK1 INHIBITOR, AS INDUCTION THERAPY IN PATIENTS WITH CROHN’S DISEASE: RESULTS FROM CELEST

William J Sanborn  1     Brian G. Feagan  2     Julian Panés  3     Geert R. D'Haens  4     Jean-Frederic Colombel  5     Qian Zhou  6     Bidan Huang     J. V. Enejosa     Aileen L Pangan     Ana P. Lacerda    
1 University of California San Diego,La Jolla,United States of America
2 Robarts Clinical Trials , Western University,London,Canada
3 Hospital Clínic Barcelona, Department of Gastroenterology,Baecelona,Spain
4 Academic Medical Centre,Amsterdam,Netherlands
5 Icahn School of Medicine at Mount Sinai,New York,United States of America
6 AbbVie In

Conference
25th UEG Week 2017

Citation
United European Gastroenterology Journal 2017; 5 (Supplement 1)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing